Assessment of ambiguous base calls in HIV-1 pol population sequences as a biomarker for identification of recent infections in HIV-1 incidence studies

Journal of Clinical Microbiology

Volumn 52, Issue 8, 2014, Pages 2977-2983

  Meixenberger, Karolin ^a   Hauser, Andrea ^a   Jansen, Klaus ^a   Yousef, Kaveh Pouran ^b   Fiedler, Stefan ^a   Von Kleist, Max ^b   Norley, Stephen ^a   Somogyi, Sybille ^a   Hamouda, Osamah ^a   Bannert, Norbert ^a   Bartmeyer, Barbara ^a   Kücherer, Claudia ^a  

^a ROBERT KOCH INSTITUTE   (Germany)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ALGORITHM; ARTICLE; CD4 LYMPHOCYTE COUNT; ENZYME IMMUNOASSAY; FEMALE; GENOTYPE; GERMANY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 SUBTYPE A; HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 SUBTYPE B; HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 SUBTYPE C; MAJOR CLINICAL STUDY; MALE; MEASUREMENT ACCURACY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SEQUENCE AMBIGUITY METHOD; SEQUENCE ANALYSIS; SEROCONVERSION; STRUCTURAL GENE; VIRUS LOAD; CLASSIFICATION; CLINICAL TRIAL; COHORT ANALYSIS; GENETIC MARKER; GENETIC VARIABILITY; GENETICS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; ISOLATION AND PURIFICATION; MULTICENTER STUDY; PROSPECTIVE STUDY; VIROLOGY;

GENETIC MARKER; POL PROTEIN;

ADULT; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; FEMALE; GENETIC MARKERS; GENETIC VARIATION; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MALE; POL GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; PROSPECTIVE STUDIES; VIRAL LOAD;

EID: 84905276869     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.03289-13     Document Type: Article

References (29)

1. Fiebig EW, Wright DJ, Rawal BD, Garrett PE, Schumacher RT, Peddada L, Heldebrant C, Smith R, Conrad A, Kleinman SH, Busch MP. 2003. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS 17: 1871-1879. http://dx.doi.org/10. 1097/00002030-200309050-00005. (Pubitemid 37070272)
2. Parekh BS, Kennedy MS, Dobbs T, Pau CP, Byers R, Green T, Hu DJ, Vanichseni S, Young NL, Choopanya K, Mastro TD, McDougal JS. 2002. Quantitative detection of increasing HIV type 1 antibodies after seroconversion: a simple assay for detecting recent HIV infection and estimating incidence. AIDS Res. Hum. Retroviruses 18:295-307. http://dx.doi.org/10.1089/088922202753472874. (Pubitemid 34253148)
3. Suligoi B, Rodella A, Raimondo M, Regine V, Terlenghi L, Manca N, Casari S, Camoni L, Salfa MC, Galli C. 2011. Avidity index for anti-HIV antibodies: comparison between third- and fourth-generation automated immunoassays. J. Clin. Microbiol. 49:2610-2613. http://dx.doi.org/10.1128/JCM.02115-10.
4. Duong YT, Qiu M, De AK, Jackson K, Dobbs T, Kim AA, Nkengasong JN, Parekh BS. 2012. Detection of recent HIV-1 infection using a new limiting-antigen avidity assay: potential for HIV-1 incidence estimates and avidity maturation studies. PLoS One 7(3):e33328. http://dx.doi.org/10.1371/journal.pone.0033328.
5. Curtis KA, Hanson DL, Kennedy MS, Owen SM. 2013. Evaluation of a multiplex assay for estimation of HIV-1 incidence. PLoS One 8(5):e64201. http://dx.doi.org/10.1371/journal.pone.0064201.
6. Parekh BS, Hanson DL, Hargrove J, Branson B, Green T, Dobbs T, Constantine N, Overbaugh J, McDougal JS. 2011. Determination of mean recency period for estimation of HIV type 1 Incidence with the BED-capture EIA in persons infected with diverse subtypes. AIDS Res. Hum. Retroviruses 27:265-273. http://dx.doi.org/10.1089/aid.2010.0159.
7. Longosz AF, Serwadda D, Nalugoda F, Kigozi G, Franco V, Gray RH, Quinn TC, Eshleman SH, Laeyendecker O. 2014. Impact of HIV subtype on performance of the limiting antigen-avidity enzyme immunoassay, the Bio-Rad avidity assay, and the BED capture immunoassay in Rakai, Uganda. AIDS Res. Hum. Retroviruses 30:339-344. http://dx.doi.org/10.1089/aid.2013.0169.
8. Wendel SK, Mullis CE, Eshleman SH, Blankson JN, Moore RD, Keruly JC, Brookmeyer R, Quinn TC, Laeyendecker O. 2013. Effect of natural and ARV-induced viral suppression and viral breakthrough on anti-HIV antibody proportion and avidity in patients with HIV-1 subtype B infection. PLoS One 8(2):e55525. http://dx.doi.org/10.1371/journal.pone.0055525.
9. Laeyendecker O, Brookmeyer R, Oliver AE, Mullis CE, Eaton KP, Mueller AC, Jacobson LP, Margolick JB, Brown J, Rinaldo CR, Quinn TC, Eshleman SH, Multicenter AIDS Cohort Study (MACS). 2012. Factors associated with incorrect identification of recent HIV infection using the BED capture immunoassay. AIDS Res. Hum. Retroviruses 28:816-822. http://dx.doi.org/10.1089/aid.2011.0258.
10. Park SY, Goeken N, Lee HJ, Bolan R, Dube MP, Lee HY. 2014. Developing high-throughput HIV incidence assay with pyrosequencing platform. J. Virol. 88:2977-2990. http://dx.doi.org/10.1128/JVI.03128-13.
11. Park SY, Love TM, Nelson J, Thurston SW, Perelson AS, Lee HY. 2011. Designing a genome-based HIV incidence assay with high sensitivity and specificity. AIDS 25: F13-F19. http://dx.doi.org/10.1097/QAD.0b013e328349f089.
12. Cousins MM, Konikoff J, Laeyendecker O, Celum C, Buchbinder SP, Seage GR, Kirk GD, Moore RD, Mehta SH, Margolick JB, Brown J, Mayer KH, Koblin BA, Wheeler D, Justman JE, Hodder SL, Quinn TC, Brookmeyer R, Eshleman SH. 2014. HIV diversity as a biomarker for HIV incidence estimation: including a high-resolution melting diversity assay in a multiassay algorithm. J. Clin. Microbiol. 52:115-121. http://dx.doi.org/10.1128/JCM.02040-13.
13. Brookmeyer R, Konikoff J, Laeyendecker O, Eshleman SH. 2013. Estimation of HIV incidence using multiple biomarkers. Am. J. Epidemiol. 177:264-272. http://dx.doi.org/10.1093/aje/kws436.
14. Kouyos RD, von Wyl V, Yerly S, Boni J, Rieder P, Joos B, Taffe P, Shah C, Burgisser P, Klimkait T, Weber R, Hirschel B, Cavassini M, Rauch A, Battegay M, Vernazza PL, Bernasconi E, Ledergerber B, Bonhoeffer S, Gunthard HF, Swiss HIV Cohort Study. 2011. Ambiguous nucleotide calls from population-based sequencing of HIV-1 are a marker for viral diversity and the age of infection. Clin. Infect. Dis. 52:532-539. http://dx.doi.org/10.1093/cid/ciq164.
15. Ragonnet-Cronin M, Aris-Brosou S, Joanisse I, Merks H, Vallee D, Caminiti K, Rekart M, Krajden M, Cook D, Kim J, Malloch L, Sandstrom P, Brooks J. 2012. Genetic diversity as a marker for timing infection in HIV-infected patients: evaluation of a 6-month window and comparison with BED. J. Infect. Dis. 206:756-764. http://dx.doi.org/10.1093/infdis/jis411.
16. Andersson E, Shao W, Bontell I, Cham F, Cuong DD, Wondwossen A, Morris L, Hunt G, Sonnerborg A, Bertagnolio S, Maldarelli F, Jordan MR. 2013. Evaluation of sequence ambiguities of the HIV-1 pol gene as a method to identify recent HIV-1 infection in transmitted drug resistance surveys. Infect. Genet. Evol. 18: 125-131. http://dx.doi.org/10.1016/j.meegid.2013.03.050.
17. Duwe S, Brunn M, Altmann D, Hamouda O, Schmidt B, Walter H, Pauli G, Kucherer C. 2001. Frequency of genotypic and phenotypic drug-resistant HIV-1 among therapy-naive patients of the German Seroconverter Study. J. Acquir. Immune Defic. Syndr. 26:266-273. http://dx.doi.org/10.1097/00126334-200103010- 00010. (Pubitemid 32246557)
18. Poggensee G, Kucherer C, Werning J, Somogyi S, Bieniek B, Dupke S, Jessen H, Hamouda O, HIV-1 Seroconverter Study Group. 2007. Impact of transmission of drug-resistant HIV on the course of infection and the treatment success. Data from the German HIV-1 Seroconverter Study. HIV Med. 8: 511-519. http://dx.doi.org/10.1111/j.1468-1293.2007.00504.x.
19. Bartmeyer B, Kuecherer C, Houareau C, Werning J, Keeren K, Somogyi S, Kollan C, Jessen H, Dupke S, Hamouda O, German HIV-1 Seroconverter Study Group. 2010. Prevalence of transmitted drug resistance and impact of transmitted resistance on treatment success in the German HIV-1 Seroconverter Cohort. PLoS One 5(10):e12718. http://dx.doi.org/10.1371/journal.pone.0012718.
20. Zu Knyphausen F, Scheufele R, Kucherer C, Jansen K, Somogyi S, Dupke S, Jessen H, Schurmann D, Hamouda O, Meixenberger K, Bartmeyer B. 2014. First line treatment response in patients with transmitted HIV drug resistance and well defined time point of HIV infection: updated results from the German HIV-1 Seroconverter Study. PLoS One 9(5):e95956. http://dx.doi.org/10.1371/journal. pone.0095956.
21. Walter H, Schmidt B, Korn K, Vandamme AM, Harrer T, Uberla K. 1999. Rapid, phenotypic HIV-1 drug sensitivity assay for protease and reverse transcriptase inhibitors. J. Clin. Virol. 13:71-80. http://dx.doi.org/10.1016/ S1386-6532(99)00010-4. (Pubitemid 29308516)
22. Bennett DE, Camacho RJ, Otelea D, Kuritzkes DR, Fleury H, Kiuchi M, Heneine W, Kantor R, Jordan MR, Schapiro JM, Vandamme AM, Sandstrom P, Boucher CA, van de Vijver D, Rhee SY, Liu TF, Pillay D, Shafer RW. 2009. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One 4(3):e4724. http://dx.doi.org/10.1371/journal.pone.0004724.
23. Kassanjee R, McWalter TA, Welte A. 2014. Short communication: defining optimality of a test for recent infection for HIV incidence surveillance. AIDS Res. Hum. Retroviruses 30:45-49. http://dx.doi.org/10.1089/aid.2013.0113.
24. Loschen S, Batzing-Feigenbaum J, Poggensee G, Cordes C, Hintsche B, Rausch M, Dupke S, Gohlke-Micknis S, Rodig J, Hamouda O, Kucherer C. 2008. Comparison of the human immunodeficiency virus (HIV) type 1-specific immunoglobulinGcapture enzyme-linked immunosorbent assay and the avidity index method for identification of recent HIV infections. J. Clin. Microbiol. 46:341-345. http://dx.doi.org/10.1128/JCM.01055-07.
25. Hauser A, Santos-Hoevener C, Meixenberger K, Zimmermann R, Somogyi S, Fiedler S, Hoffmann A, Bartmeyer B, Jansen K, Hamouda O, Bannert N, Kuecherer C. 2014. Improved testing of recent HIV-1 infections with the BioRad Avidity Assay compared to the Limiting Antigen Avidity Assay and BED Capture Enzyme Immunoassay: evaluation using reference sample panels from the German Seroconverter Cohort. PLoS One 9(6):e98038. http://dx.doi.org/10.1371/journal. pone.0098038.
26. Laeyendecker O, Brookmeyer R, Mullis CE, Donnell D, Lingappa J, Celum C, Baeten JM, Campbell MS, Essex M, de Bruyn G, Farquhar C, Quinn TC, Eshleman SH, Partners in Prevention HSV/HIV Transmission Study Team. 2012. Specificity of four laboratory approaches for cross-sectional HIV incidence determination: analysis of samples from adults with known nonrecent HIV infection from five African countries. AIDS Res. Hum. Retroviruses 28:1177-1183. http://dx.doi.org/10.1089/aid.2011.0341.
27. Karita E, Price M, Hunter E, Chomba E, Allen S, Fei L, Kamali A, Sanders EJ, Anzala O, Katende M, Ketter N, IAVI Collaborative Seroprevalence and Incidence Study T. 2007. Investigating the utility of the HIV-1 BED capture enzyme immunoassay using cross-sectional and longitudinal seroconverter specimens from Africa. AIDS 21:403-408. http://dx.doi.org/10.1097/QAD. 0b013e32801481b7.
28. Li H, Bar KJ, Wang S, Decker JM, Chen Y, Sun C, Salazar-Gonzalez JF, Salazar MG, Learn GH, Morgan CJ, Schumacher JE, Hraber P, Giorgi EE, Bhattacharya T, Korber BT, Perelson AS, Eron JJ, Cohen MS, Hicks CB, Haynes BF, Markowitz M, Keele BF, Hahn BH, Shaw GM. 2010. High multiplicity infection by HIV-1 in men who have sex with men. PLoS Pathog. 6 (5):e1000890. http://dx.doi.org/10.1371/journal.ppat.1000890.
29. Bar KJ, Li H, Chamberland A, Tremblay C, Routy JP, Grayson T, Sun C, Wang S, Learn GH, Morgan CJ, Schumacher JE, Haynes BF, Keele BF, Hahn BH, Shaw GM. 2010. Wide variation in the multiplicity of HIV-1 infection among injection drug users. J. Virol. 84:6241-6247. http://dx.doi.org/10.1128/JVI.00077-10.